{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-185324","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.625236+00:00","generated_at":"2026-06-24T21:57:32.608128+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China","bullets":["EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.","Aadi disputes EOC's allegations of material breach; believes termination is for convenience.","Aadi had received $14M upfront and $1M milestone; lost potential $257M in milestones and royalties.","No further payments from EOC expected; Aadi loses exclusive development/commercialization partner for China."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-185324","json":"https://secwatch.observer/filing/0001193125-22-185324.json","markdown":"https://secwatch.observer/filing/0001193125-22-185324.md","text":"https://secwatch.observer/filing/0001193125-22-185324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/0001193125-22-185324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/d360965d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:57:32.608128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}